Biotech Acquisition Company and Blade Therapeutics Announced Postponement of Extraordinary Meeting of Shareholders to Approve Proposed Business Combination from June 1 to June 3

Biotech Acquisition Company (NASDAQ:BIOT) ("BAC"), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, and Blade Therapeutics, Inc. ("Blade"), a biopharmaceutical company based in South San Francisco, Calif., today announced the postponement of BAC's extraordinary general meeting of shareholders (the "Extraordinary Meeting") originally scheduled to be held on June 1, 2022. The Extraordinary Meeting has been postponed until June 3, 2022, at 10:00 a.m. Eastern Time. As previously announced, the Extraordinary Meeting will occur at the offices of Ellenoff Grossman and Schole LLP located at 1345 Avenue of the Americas, 11th Floor, New York, New York, 10105 and virtually via live webcast at https://www.cstproxy.com/biotechacquisition/2022.  The Extraordinary Meeting is being held to vote on the proposals described in BAC's definitive proxy statement, filed with the Securities and Exchange Commission (the "SEC") on May 9, 2022, as supplemented by a Prospectus Supplement dated May 23, 2022 relating to the previously announced proposed business combination with Blade. The record date for the determination of shareholders entitled to vote at the Extraordinary Meeting, including all adjournments thereof, remains March 28, 2022. The BAC Board of Directors continues to recommend that shareholders vote in favor of the proposals. As of the date of this press release, a sufficient number of BAC's shareholders have voted to approve the proposed business combination. The postponement of the Extraordinary Meeting is intended to permit more time to satisfy all conditions necessary to effect the closing of the proposed Business Combination. BAC shareholders who have any questions or who need assistance voting their shares may contact BAC's proxy solicitor, Morrow Sodali LLC, by calling (800) 662-5200 (or banks and brokers can call collect at (203) 658-9400) or by emailing [email protected].